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Abstract
Background: Recent studies in Mali, Nigeria, and Senegal have indicated that annual (or biannual) ivermectin distribution
may lead to local elimination of human onchocerciasis in certain African foci. Modelling-based projections have been used
to estimate the required duration of ivermectin distribution to reach elimination. A crucial assumption has been that
microfilarial production by Onchocerca volvulus is reduced irreversibly by 30–35% with each (annual) ivermectin round.
However, other modelling-based analyses suggest that ivermectin may not have such a cumulative effect. Uncertainty in
this (biological) and other (programmatic) assumptions would affect projected outcomes of long-term ivermectin
treatment.
Methodology/Principal Findings: We modify a deterministic age- and sex-structured onchocerciasis transmission model,
parameterised for savannah O. volvulus–Simulium damnosum, to explore the impact of assumptions regarding the effect of
ivermectin on worm fertility and the patterns of treatment coverage compliance, and frequency on projections of
parasitological outcomes due to long-term, mass ivermectin administration in hyperendemic areas. The projected impact of
ivermectin distribution on onchocerciasis and the benefits of switching from annual to biannual distribution are strongly
dependent on assumptions regarding the drug’s effect on worm fertility and on treatment compliance. If ivermectin does
not have a cumulative impact on microfilarial production, elimination of onchocerciasis in hyperendemic areas may not be
feasible with annual ivermectin distribution.
Conclusions/Significance: There is substantial (biological and programmatic) uncertainty surrounding modelling
projections of onchocerciasis elimination. These uncertainties need to be acknowledged for mathematical models to
inform control policy reliably. Further research is needed to elucidate the effect of ivermectin on O. volvulus reproductive
biology and quantify the patterns of coverage and compliance in treated communities.
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Introduction
Human onchocerciasis, caused by Onchocerca volvulus and
transmitted by Simulium blackflies, is a parasitic disease leading
to ocular (vision loss, blindness) and cutaneous (itching, dermatitis,
depigmentation) pathology [1,2], as well as to increased host
mortality [3,4,5].
The Onchocerciasis Control Programme in West Africa (OCP)
started in 1974. The programme was initially based on vector
control until, in 1987, ivermectin was registered for human use
against onchocerciasis. Thereupon, Merck & Co. Inc. took the
unprecedented decision to donate ivermectin for as long as needed
to eliminate onchocerciasis as a public health problem [6]. Mass
drug administration (MDA) of ivermectin began in some OCP
regions in 1988–1989, particularly in extension areas [7]. In some
areas of the OCP both antivectorial and antiparasitic measures
were combined, whilst in others (mainly in the western extension)
ivermectin distribution alone, annually or biannually, was
implemented [7,8]. The African Programme for Onchocerciasis
Control (APOC) was launched in 1995 to target the 19
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onchocerciasis endemic countries in Africa not covered by the
OCP [8,9]. APOC’s strategy involved the establishment of
effective and sustainable, community-directed, annual mass
ivermectin treatment for all those aged five years and older
[10,11]. The programme, initially conceived to end in 2007 [8],
and subsequently in 2015 [12], has recently been extended until
2025 with the new goal and commitment for the elimination of
onchocerciasis [13].
In addition to OCP western extension areas that were treated
twice-yearly (e.g. Senegal [7]), some countries such as Ghana (in
the former OCP), and Uganda (in APOC), have adopted a
biannual treatment strategy in selected foci; the former because of
suspected suboptimal responses to ivermectin treatment [14], and
the latter because, in combination with vector control, elimination
may be accelerated [15,16].
Ivermectin is a potent microfilaricide, causing a greater than
90% reduction in skin microfilarial load within a few days, and a
maximum reduction of 98–99% two months after treatment [17].
Ivermectin also has an embryostatic effect on adult female worms,
temporarily blocking the release of microfilariae (mf) [18]. The
efficacy of the embryostatic effect is approximately 70%, with the
maximum reduction of microfilarial production reached one to
two months after treatment [17]. Recuperation of adult worms’
fertility occurs slowly from three to four months after treatment
onwards [17,18] but may not regain its original level up to 18
months after treatment. (The term fertility is used here to refer to
worms producing live, stretched mf, by contrast with females
producing oocytes or embryos, which would correspond to worm
fecundity [17].)
Recent epidemiological and entomological evaluations conduct-
ed in Mali and Senegal suggest that 15–17 years of annual (or
biannual) ivermectin distribution (in the absence of vector control)
may be sufficient to lead to local onchocerciasis elimination in
certain foci [19]. In addition, local elimination may have been
achieved with 15–17 years of ivermectin distribution in 26 villages
in Kaduna state, Nigeria (the first report of such evidence for the
operational area of APOC) [20]. These studies have provided
proof of principle that elimination with annual ivermectin
distribution may be feasible in some African foci. In 2009, an
international expert group convened to discuss the implications of
these results [21]. Based on experiences with cessation of
onchocerciasis control in West Africa and predictions from
mathematical models, the group developed an operational
framework for elimination and provisionally defined transmission
thresholds, namely, a microfilarial prevalence below 5% in all
surveyed villages (and below 1% in 90% of the villages), and a
proportion of local simuliid vectors harbouring ,0.5 L3 larvae per
1,000 flies [19,21].
Mathematical models such as [22], have been used to assess the
feasibility of, and predict the duration of ivermectin distribution
required for elimination [23]. In these modelling projections,
overall (therapeutic) treatment coverage was varied as part of the
sensitivity analysis, and those not taking treatment included a
(correlated but unreported) fraction of systematic non-compliers.
However, the effect of systematic non-compliers (i.e. the
proportion of the population aged five years and older who
never take treatment) on the feasibility of elimination was not
investigated independently from that of coverage. A crucial
conjecture of these projections (based on analysis of a 5-year
community ivermectin trial in Asubende, Ghana [24]), was that
adult female worms, after temporarily ceasing microfilarial
production due to the embryostatic effect of ivermectin, gradually
reach a new production level which is reduced irreversibly by an
average of 30–35% after each treatment round [25], effectively
assuming a cumulative effect of ivermectin on female worm
fertility (equivalent to an increasing proportion of worms not
contributing to transmission; a sort of ‘macrofilaricidal’ effect
[23,25]). However, another modelling study, using data from a
community trial with five biannual treatment rounds in
Guatemala [26], did not find evidence for a cumulative effect
on microfilarial production [27].
Whether or not ivermectin has a cumulative effect on female
worm fertility [28,29] will have important implications for the
optimal design of MDA programmes, and given the sparse data
that exist, this issue represents an area of considerable uncertainty
which needs to be taken into account in modelling studies
estimating the long-term impact of ivermectin treatment on
parasite populations in humans and vectors.
In this paper, we modify our current onchocerciasis transmis-
sion model [30] to explore the uncertainty in modelling
projections of the long-term impact of ivermectin on O. volvulus
populations due to assumptions concerning: a) the effect of
ivermectin on mf production by female worms (biological
variables), and b) treatment coverage and compliance (program-
matic variables). We also explore how these affect the benefit of
annual vs. biannual treatment frequency.
Methods
Mathematical Model
We modified our sex- and age-structured deterministic oncho-
cerciasis transmission model [30,31], which describes the rate of
change with respect to time and host age of the mean number of
fertile and non-fertile female adult worms per host, the mean
number of microfilariae per milligram (mg) of skin (mf/mg), and
the mean number of infective (L3) larvae per fly. To obtain
infection prevalence from infection intensity in humans, we
assumed that the distribution of mf among hosts is negative
binomial as described in [32]. A detailed description of the model
equations is given in Supporting Information Text S1: Protocol
S1, Onchocerciasis Population Dynamics Model. Parameter definitions
Author Summary
Studies in Mali, Nigeria, and Senegal suggest that, in some
settings, it is possible to eliminate onchocerciasis after 15–
17 years of ivermectin distribution. Computer models have
been used to estimate the required duration of ivermectin
distribution to reach elimination. Some models assume
that annual ivermectin treatment reduces the fertility of
the causing parasite, Onchocerca volvulus, by 30–35% each
time the drug is taken. Other analyses suggest that
ivermectin may not have such an effect. We explore how
assumptions regarding: a) treatment effects on microfilar-
ial production by female worms (fertility), b) proportion of
people who receive the drug (coverage), c) proportion of
people who adhere to treatment (compliance), and d)
whether people are treated once or twice per year
(frequency) affect temporal projections of infection load
and prevalence in highly endemic African savannah
settings. We find that if treatment does not affect parasite
fertility cumulatively, elimination of onchocerciasis in
highly endemic areas of Africa may not be feasible with
annual ivermectin distribution alone. If two areas have
equal coverage but dissimilar compliance, they may
experience very different infection load, prevalence and
persistence trends. Projections such as these are crucial to
help onchocerciasis control programmes to plan elimina-
tion strategies effectively.
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and values can be found in Supporting Information Text S2:
Supplementary Tables, Table S1.
Ivermectin Effects
After each dose of ivermectin there is a microfilaricidal effect
with 99% efficacy, and a reduction in microfilarial production
(embryostatic effect) by fertile female worms [17]. The ivermectin-
exposed adult worms are then assumed either to: a) reach a new
microfilarial production rate which is reduced by 30% ten months
after each treatment round (representing a cumulative effect,
depicted in Figure 1A), or b) resume microfilarial production,
which ten months after each treatment would reach 70% of its
baseline value, i.e. is also reduced by 30% from baseline, but the
reduction is not additive (representing a non-cumulative effect, as
concluded in [27], and illustrated in Figure 1B). The equations
modelling the effect of ivermectin in female worm fertility are
described in Supporting Information Text S1: Protocol S2,
Modelling the Cumulative Effect of Ivermectin. Parameter definitions
and values can be found in Supporting Information Text S2:
Supplementary Tables, Table S2.
Although the cumulative reduction proposed in [25] was
estimated from data corresponding to annual ivermectin distribu-
tion [24], it was assumed that in the case of biannual treatments,
each 6-monthly treatment causes the same proportional reduction.
An analysis of the sensitivity of model outputs to this assumption
was conducted following [23]. Ivermectin was assumed to have no
macrofilaricidal action (i.e. not to reduce adult worm life-
expectancy) at the standard dose used for MDA [17,33,34], and
to have intact efficacy, i.e., no sub-optimal response [14] or drug
resistance [35] were included.
Treatment Coverage, Compliance, and Frequency
The model is stratified into four treatment compliance classes: a
first group of individuals who take treatment every round; two
groups who take treatment every other round alternately, and a
fourth group who never take treatment. The latter class represents
individuals in the community who are systematic non-compliers, as
opposed to a situation in which a proportion of individuals miss
some treatment rounds (e.g. because they are absent or pregnant at
the time of treatment). The proportion of systematic non-compliers
was set at 0.1%, 2%, and 5% to investigate its effect on model
outputs. These values were chosen to explore potential variability in
this parameter. A recent ivermectin compliance study reported that
6% had never taken the drug over the course of eight consecutive
treatment rounds [36]. The four compliance groups were assumed
not to differ in exposure to vectors (which depends on age and sex
according to [30]). Children under five years were not treated in the
model as they are not eligible to receive ivermectin.
Figure 1. Schematic representation of two different proposed effects of ivermectin on Onchocerca volvulus microfilarial production.
The schematic represents a closed population of adult worms (i.e., no incoming worms due to transmission or worm death). A: Ivermectin is assumed
to have a cumulative effect on adult worm fertility by which the microfilarial production of ivermectin-exposed adult worms is reduced by 30% after
each treatment round (red solid line). B: Ivermectin is assumed not to have a cumulative effect; ivermectin-exposed adult worms resume microfilarial
production to 70% of its baseline value ten months after each treatment [17] (blue solid line).
doi:10.1371/journal.pntd.0002169.g001
Projected Impact of Ivermectin on Onchocerciasis
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Model Parameterisation and Examined Outputs
Human age- and sex-structure reflects the demography in
savannah areas of northern Cameroon [37,38], as it is in
savannah areas of Africa that the prevailing O. volvulus–S.
damnosum combinations are responsible for the most severe
sequelae of onchocerciasis [1,2]. Parameters for vector compe-
tence, survival, and host choice were those for savannah species
of the Simulium damnosum complex (S. damnosum sensu stricto and S.
sirbanum) [30,39], responsible for onchocerciasis transmission in
the region [40,41].
The overdispersion parameter for the distribution of adult
worms among hosts was as estimated in [27] (see Supporting
Information Text S1: Protocol S3, Mating Probability and
Supporting Information Text S2: Supplementary Tables, Table
S3). The parameterisation of the relationship between microfi-
larial prevalence and load was that for West African savannah
areas [32] (see Supporting Information Text S1: Protocol S4,
Microfilarial Prevalence and Supporting Information Text S2:
Supplementary Tables, Table S3). The annual biting rate
(ABR) by blackfly vectors was set to 19,000 bites per person
per year (well within the range of values recorded in savannah
areas [32,40,41]), to achieve a baseline mean microfilarial load of
27 mf/mg (all ages), and of 44 mf/mg of skin in those aged 20
years and above. This resulted in an overall microfilarial
prevalence (all ages) of 70%, representing an area of high
baseline endemicity. In onchocerciasis, hyperendemic areas are
those with overall infection prevalence above 60% [42], but this
class can encompass a wide range of transmission and infection
intensities. (Note that the mean microfilarial load per mg of skin
in those aged $20 years here is an arithmetic mean, not a
geometric mean of the number of microfilariae per skin snip (ss)
(mf/ss) in the same age group, known as the community
microfilarial load (CMFL) [43].) Understanding the long-term
impact of ivermectin in highly hyperendemic areas is particularly
important, as such areas will be those in which controlling the
disease has the highest priority (morbidity will be more severe),
elimination of the infection reservoir is likely to be more difficult
or take longer [23], and from which the infection could reinvade
controlled areas.
The model was used to explore the effect of 15 years of (annual
or biannual) mass ivermectin distribution on: a) infection intensity
defined as mean microfilarial load per mg of skin in those aged
$20 years, and b) prevalence of microfilaridermia in the overall
population. We choose 15 years as a suitable timescale to
investigate the impact of long-term treatment of onchocerciasis
with ivermectin, motivated by the epidemiological studies
described in [19,20]. Since the model is deterministic, the
probability of reaching elimination was not investigated.
Sensitivity Analysis
The sensitivity of the above model outputs was explored
regarding the following assumptions: 1) cumulative effect of
ivermectin on female worm fertility (present vs. absent); 2) overall
therapeutic coverage (proportion of the total population receiving
ivermectin at each round: 60%, 70%, 80%); 3) proportion of
systematic non-compliers (those who never take treatment: 0.1%,
2%, 5%); and 4) treatment frequency (annual vs. biannual). In
order to explore the extent to which our results were sensitive to
the assumption that biannual treatments each caused the same
reduction in fertility of 30% per treatment; we also explored model
outputs with a more conservative reduction of 16.5% per 6-
monthly treatment (which gives an overall annual reduction of
30%).
Results
Cumulative vs. Non-cumulative Effect of Ivermectin on
Microfilarial Production by O. volvulus
Model outputs indicate that the assumption of a cumulative
impact of ivermectin on microfilarial production by female O.
volvulus has a substantial effect on projections of long-term
ivermectin treatment (Figure 2). Regarding infection intensity in
adults aged 20 years and older, there would be a very pronounced
decrease partly due to little repopulation of the skin by mf, and
partly due to the ensuing suppressed transmission. This is because,
under this conjecture, the model assumes that the number of mf
produced per female worm per unit time would progressively be
reduced to a very low level. By contrast, under the assumption of
ivermectin not exerting a cumulative effect on microfilarial
production, there is a substantial amount of repopulation of the
skin by mf in-between annual treatments, leading to more
transmission and a smaller impact on infection intensity.
Annual vs. Biannual Treatment Frequency
Assumptions regarding the operation or absence of a cumulative
effect of ivermectin on parasite fertility can also influence the
expected relative benefits of annual vs. biannual treatment
frequency regarding reductions in infection intensity, prevalence,
and transmission. In the presence of a cumulative reduction with
each treatment round, there is initially a very marked benefit of the
biannual distribution on the reduction of parasitological indicators
(as the rate of microfilarial production is rapidly reduced).
However, after repeated treatments, there would be much less
difference in the long-term impact of ivermectin treatment on
microfilarial prevalence compared to an annual treatment strategy
(Figure 3A). In the absence of a cumulative effect, biannual
treatments are more beneficial both in the short and long terms in
Figure 2. Impact on infection intensity of annual ivermectin
distribution under two assumptions of ivermectin effects.
Intensity of infection is quantified as microfilarial load per mg of skin
in those aged $20 years. The red and blue solid lines represent,
respectively, model outputs assuming the operation of a cumulative
impact on the fertility of O. volvulus (illustrated in Fig. 1A), or the
absence of such an effect (Fig. 1B). Model calibration corresponds to an
ABR of 19,000 (savannah) Simulium damnosum bites/person/year; a
baseline mean microfilarial load of 44 mf/mg (in those aged$20 years);
a 70% microfilarial prevalence (all ages); a therapeutic coverage of 80%
(overall population); and a systematic non-compliance rate of 0.1%. The
demography of the human population is that of northern Cameroon
[30,37,38].
doi:10.1371/journal.pntd.0002169.g002
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reducing microfilarial prevalence than annual treatments
(Figure 3B). With the more conservative 16.5% reduction in
female fertility per 6-monthly treatment, the initial benefit of
microfilarial prevalence reduction is less pronounced than in the
previous scenario, but again, there is relatively little difference in
the long-term impact of biannual compared to annual ivermectin
treatments (Supporting Information Text S3: Supplementary
Figures, Figure S1).
Therapeutic Coverage and Compliance Patterns
Varying the therapeutic coverage in the overall population, and
the proportion of systematic non-compliers had a large influence
on the infection intensity achieved at the end of the 15th year of
ivermectin distribution. An increased overall coverage, or a
decreased proportion of systematic non-compliers lead to lower
microfilarial loads 12 months after the 15th year of intervention
(Figure 4). Under annual treatment, overall coverage had a larger
effect on projected infection intensity (Figure 4A) and microfilarial
prevalence (Supporting Information Text S3: Supplementary
Figures, Figure S2A) than under biannual treatment (Supporting
Information Text S3: Supplementary Figures, Figure 4B and
Figure S2B). (Because of the nonlinear relationship between
infection prevalence and intensity, the proportional reductions in
prevalence are smaller.) For instance, under the assumption of a
cumulative effect of ivermectin, and for a 5% proportion of non-
compliers, increasing therapeutic coverage from 60% to 80%
decreased microfilarial load by ,50% for annual frequency
compared to 16% for biannual frequency. The corresponding
values when no cumulative effect was assumed were ,37% and
,30%. By contrast, the assumed proportion of systematic non-
compliers had a more pronounced effect on the impact of biannual
treatment delivery. Under the assumption of a cumulative effect of
ivermectin, and for a 70% therapeutic coverage, decreasing
systematic non-compliance from 5% to 0.1% decreased microfi-
larial load by ,69% for annual frequency and by ,97% for
biannual frequency. The corresponding values when no cumula-
tive effect was assumed were ,23% and ,53%.
Discussion
Cumulative vs. Non-cumulative Effect of Ivermectin on
Microfilarial Production by O. volvulus
Mathematical models can play a fundamental role in informing
control programmes and strategies, but crucially, policy makers
must realise that model outputs are highly dependent on implicit
and explicit model assumptions [44]. Among the latter and for
onchocerciasis in particular, the effects that (yearly or 6-monthly)
ivermectin treatments exert on the reproductive biology of O.
volvulus represent an area of considerable uncertainty, where
further research is urgently needed. Although ivermectin’s
Figure 3. Impact on infection prevalence of annual/biannual ivermectin distribution under two assumptions of ivermectin effects.
Solid and dashed lines represent, respectively, annual and biannual treatment frequency. A: Red lines correspond to model outputs assuming that
ivermectin exerts a cumulative reduction in microfilarial production by the adult female worm. B: Blue lines correspond to model outputs assuming
the absence of such cumulative reduction. Calibration of the model is as in Figure 2.
doi:10.1371/journal.pntd.0002169.g003
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microfilaricidal effect is well established [17], the embryostatic
effect and its repercussions on female worm fertility [18]; whether
or not such effects on fertility are irreversible [25,28]; the rate of
resumption of microfilarial production [17]; and possible effects on
intranodular sex ratios and insemination rates [45,46,47], remain
poorly understood. An appropriate and updated incorporation of
these effects into models, and an understanding of any enhanced
macrofilaricidal activity of ivermectin under increased treatment
frequency regimes [45,47,48,49], are essential to reliably inform
control policy, and fully assess ivermectin efficacy. Our results
illustrate that the question of whether or not the drug effects on
microfilarial production are cumulative, is highly influential on the
projections of the long-term effect of annual or biannual MDA
with ivermectin, particularly in areas with high baseline oncho-
cerciasis endemicity.
The data that informed the model in [25], and presented in
[24], comprised longitudinal microfilarial load follow up at various
time-points after each of five annual treatment rounds in 74
individuals who received all five annual ivermectin doses from
1987 through to 1991 in an early community trial in the savannah
focus of Asubende, Ghana [24]. The focus had been under vector
control since 1986 during the OCP, and experienced a 70%
reduction in parasite exposure during the trial despite antivectorial
measures being interrupted for the first three years of ivermectin
treatment. Figure 3 of [25] contrasts two model fits explaining the
temporal trends in five annual data points of [24], corresponding
to (decreasing) microfilarial counts just before each treatment
round. The two hypotheses being tested to explain such trends are
a null hypothesis of all—ivermectin-exposed—adult worms
regaining their full microfilarial productivity vs. an alternative
hypothesis of a 35% reduction in productivity with each treatment
round. The authors of [25] concluded that the model assuming the
alternative hypothesis provided a better fit to the data. However,
given that: a) microfilarial loads were measured per skin snip
instead of per mg of skin; b) the weight of a skin snip may range
between 0.5 and 3 mg; c) lighter snips more likely yield a false
negative result, and d) microfilarial counts originated from snips
incubated for only 30 minutes in distilled water [24,50] (likely to
underestimate microfilarial load as microfilaridermia decreases),
there is the possibility of considerable measurement error [5]. This
is particularly important regarding the last two data points in the
dataset (the most influential for discriminating between the two
Figure 4. The effect of coverage and compliance on infection intensity after 15 years of ivermectin treatment. Intensity of infection is
quantified as microfilarial load per mg of skin in those aged $20 years. The values presented correspond to one year after the 15th treatment (for
annual frequency, Fig. 4A), or one year after the 30th treatment (for biannual frequency, Fig. 4B). Red and blue bars represent, respectively, a
cumulative and a non-cumulative effect of ivermectin on microfilarial production by the female worm. Dotted bars: 0.1% systematic non-compliance;
hashed bars: 2% systematic non-compliance; solid bars: 5% systematic non-compliance. Calibration of the model is as in Figure 2. Note the different
scale on the vertical axis between 4A and 4B.
doi:10.1371/journal.pntd.0002169.g004
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hypotheses), as for the last two years of the community trial in
Asubende, the study area was receiving full vector control in
addition to ivermectin, making it difficult to disentangle the effects
of treatment from those of antivectorial measures. (The authors of
[25] indicate, however, that the impact of vector control was taken
into account in their model.) By contrast, the study in [27], based
on the data presented in [26], which did not detect a cumulative
effect of ivermectin on the production of microfilariae by female
worms, used longitudinal data from 510 individuals (7 times as
many as [24]), who took all five 6-monthly doses of ivermectin
from 1998 to 1990 in the absence of vector control in Guatemala,
with microfilarial loads measured per mg of skin after 24 h
incubation [26].
Since our current model is deterministic, we cannot presently
explore the probability of elimination. However, comparison of
our projections with those of other models is informative.
ONCHOSIM projections indicate that with a coverage of 80%,
and an initial intensity of 70 mf/ss (in those aged 20 years and
older), a minimum of 25 years of annual ivermectin distribution
would be necessary to achieve a 99% probability of elimination
[21]. In previous projections with the same model [23], the
required duration of ivermectin distribution increases steeply and
nonlinearly as heterogeneity in individual variation to vector
exposure increases. Our model includes age- and sex-dependent
exposure to vector bites [30] but does not consider inter-individual
variation. The simulations in [21,23] assume that ivermectin has a
cumulative effect on the production of mf by female worms, and
our results suggest that, in the absence of such an effect, ivermectin
would have a less pronounced long-term impact. This indicates
that if ivermectin does not have a cumulative effect on the fertility
of O. volvulus, a longer duration of ivermectin distribution than
previously estimated may be required to reach elimination
thresholds, especially in areas with a high initial infection intensity
and perennial transmission. In some areas of Cameroon that have
received 13 years of ivermectin treatment, recent analyses of
microfilarial dynamics do not support the operation of a strong
cumulative effect of repeated treatments on the microfilarial
productivity of female worms [51].
Comparison with provisional thresholds for elimination is also
interesting. Operational thresholds based on [19,21] suggest a
microfilarial prevalence ,5% in all of the sampled villages, or
,1% in 90% of sampled villages. Our results indicate that
microfilarial prevalence would remain above 5% after 15 years of
annual or biannual treatment if ivermectin does not affect
microfilarial production by O. volvulus cumulatively, even with a
therapeutic coverage of 80% and only 0.1% of non-compliers
(Figure 3B). Our hypothetical baseline infection levels were set at
70% microfilarial prevalence and .40 mf/mg in those aged $20
years, and the ABR to 19,000 bites per person per year, with
perennial transmission. The baseline prevalence in the Senega-
lese/Malian foci reporting elimination ranged from mesoendemi-
city to the lower end of hyperendemicity (20% to .60%), and the
CMFL from 10 to 48 mf/ss in 16 (27%) of the villages, with
CMFL ,10 in the remaining 44 (73%) of the 60 surveyed villages.
In addition, transmission in these foci is seasonal as opposed to
perennial, enhancing the impact of annual treatment on trans-
mission when ivermectin is distributed just before the start of the
rains; microfilarial loads are lowest during the transmission season
and there are no blackflies around to ingest mf when these start
reappearing in the skin [19]. Also, the difference with a biannual
strategy would be less pronounced. These factors may have
contributed to the feasibility of elimination in these areas and the
reported lack of a significant difference between annual and 6-
monthly treatment frequency. Likewise, in the foci located in
Kaduna state, Nigeria, the median baseline prevalence was 52%,
the median CMFL was 4 mf/ss, and transmission was also
seasonal [20]. It should be noted that ONCHOSIM projections
are consistent with current observations of elimination [19,20,21].
However, as described above, the areas where elimination has
currently been achieved had lower baseline endemicity levels, and
seasonal vector presence, leading to less transmission during inter-
treatment periods. Under these conditions, assumptions of
ivermectin effects on adult worms would likely have a lesser effect
on models projections.
Our results are compatible with those of other modelling studies
[52], which indicate that the higher the transmission intensity, the
higher the necessary effectiveness of treatment (a net measure
comprising coverage, number of treatment rounds per year and
drug efficacy) to reach elimination. However, our study also
emphasizes how different modelling assumptions can have
profound effects on model outcomes and conclusions (a more
extensive summary of the main structural assumptions of different
onchocerciasis models is presented in [53]). This further highlights
the need, discussed in [44] for helminth modellers to investigate
key questions regarding helminth control more collaboratively,
exploring the reasons for any disparity between the results of
different models using the best available data.
Annual vs. Biannual Treatment Frequency
Biannual ivermectin treatment was found to have a large
additional benefit in both reducing microfilarial prevalence and
intensity compared to annual treatment when no cumulative
reduction in parasite fertility was assumed. When such effect was
assumed, the model indicated that there would be an initial
substantial benefit (as rates of microfilarial production are reduced
quickly) of the biannual strategy, but that there would be relatively
little difference in microfilarial prevalence at the end of the 15th
year compared to annual treatment (Figure 3A). A possible reason
for the pronounced difference between the two treatment
frequencies, if ivermectin does not decrease worm fertility
cumulatively, is that there would be substantially more transmis-
sion between annual than between 6-monthly treatments (distrib-
uting the drug every 6 months does not allow the adult worms to
regain their fertility to a substantial level if there is perennial
transmission, but there may be less additional benefit in seasonal
transmission scenarios). Understanding ivermectin’s effect on the
reproduction and survival of adult worms [17,18,28,29,
45,46,47,48,49] has important policy implications regarding
switching to a biannual (or more frequent) treatment strategy in
Africa. Three-monthly ivermectin treatments have contributed to
acceleration towards local elimination in initially hyperendemic
foci in Mexico [54].
Therapeutic Coverage
Varying therapeutic coverage (for fixed non-compliance) had
less effect on the impact achieved with a biannual treatment
frequency than it had for annual distribution. This can be
explained as the model accounts for the fact that if someone misses
a treatment round, there is another chance to get treated during
that year, ensuring that at least one annual treatment is received.
In annual frequency, a missed treatment would result in a gap of at
least two years between treatments, allowing microfilaridermia
levels to build-up and contribute to transmission in the between-
treatments period. This has implications regarding policy decisions
in areas that have been found to have low coverage in the past,
and highlights the potential benefit of switching to a biannual
treatment strategy. In any case, a higher therapeutic coverage
would prevent more disease during the intervention as the
Projected Impact of Ivermectin on Onchocerciasis
PLOS Neglected Tropical Diseases | www.plosntds.org 7 April 2013 | Volume 7 | Issue 4 | e2169
intensity of infection would decrease more rapidly. Incidence of
blindness [55], and relative risk of excess mortality in sighted
individuals [4,5] depend on microfilarial load. It is also important
to bear in mind that our model, at this stage, does not include the
possibility of sub-optimal response or resistance to ivermectin or
financial costs, in which case, the described benefits of a biannual
treatment frequency could be very different.
Compliance Patterns
Assumptions regarding the proportion of systematic non-
compliers were found to be just as important as those for overall
coverage when projecting the long-term impact of ivermectin
distribution. The proportion of systematic non-compliance (for a
fixed level of therapeutic coverage) was also found to have a
marked influence on the impact achieved by a biannual strategy,
particularly when assuming a cumulative effect of ivermectin; the
higher the non-compliance rate, the smaller the benefit of
biannual treatment. This indicates that the effect of systematic
non-compliance may not simply be overcome by increasing
treatment frequency and has implications when considering
switching to a biannual treatment strategy, as two areas with the
same overall coverage but different proportion of systematic non-
compliers may lead to very different results regarding the
feasibility of elimination [56].
As control programmes move towards elimination goals, the
proportion of systematic non-compliers in the population becomes
increasingly important. Studies of coverage and compliance for
lymphatic filariasis treatment have indicated that, in addition to
heterogeneity in transmission and vector density, and missed
rounds of MDA, continuing transmission seems to be linked to
rates of systematic non-compliance [56]. Therefore, when
evaluating the progress of elimination programmes, the proportion
of, and factors contributing to, systematic non-compliance should
be investigated in addition to those determining overall coverage
[36,57], as an assessment of the latter on its own may mask reasons
behind transmission persistence.
Modelling studies should also routinely vary the proportion of
systematic non-compliers in addition to levels of treatment
coverage as part of their sensitivity analysis to help understand
the impact of prolonged treatment in populations. Although there
are some data indicating that treatment compliance may depend
on host age and sex (Brieger et al. found that older members of the
community were more likely to take ivermectin than younger
sections of the population, and men were more likely to comply
than women in a Cameroon, Nigeria and Uganda multi-centre
study [57]), further investigation regarding patterns of systematic
non-compliance (i.e. the characteristics of individuals who never
take the drug) will be essential to parameterise such modelling
studies.
Conclusions and Future Directions
There is substantially more uncertainty surrounding model-
derived projections of the long-term impact of, and feasibility of
onchocerciasis elimination with ivermectin distribution than
previously recognised. This uncertainty arises from an incomplete
understanding of the effects of ivermectin on parasite survival,
population structure, and reproductive biology, when the drug is
administered at the standard dose annually, biannually (or more
frequently, e.g. quarterly). Although the results presented in
[45,46,47,48,49] would be invaluable to parameterise mathemat-
ical models incorporating such effects, further empirical and
theoretical research is needed. Regarding the former, there is a
need for well-characterized long-term (individual) longitudinal
data (including previous treatment history), to estimate reliably the
potential macrofilaricidal effects of ivermectin. However, to avoid
the potentially confounding effect of ongoing transmission (which
may lead to underestimating macrofilaricidal effects, particularly
under annual treatment), studies could be conducted in areas
where transmission has been interrupted (in geographical or
ecological islands by elimination of the local vector [58,59]). In
areas near to elimination due to ivermectin distribution alone,
rates of skin repopulation by mf could be investigated by fitting
models to these data under a variety of ivermectin effects
assumptions. Regarding the more theoretical aspects, a more
adequate formulation of the parasite’s mating probability in light
of drug effects, decreasing male to female sex ratios [60], and
changes in parasite distribution resulting from prolonged treat-
ment [61] would also be important for assessing the feasibility of
elimination.
Our results indicate that in areas with high baseline endemicity
and perennial transmission, 15 years of annual or biannual
treatment with ivermectin may not be sufficient to bring infection
levels below potential elimination thresholds. Further incorpora-
tion of ivermectin effects into models; comparison of perennial vs.
seasonal patterns of transmission; consideration of other O.
volvulus–Simulium combinations; calibration of models for a wide
range of baseline endemicity levels; assessment of patterns of
treatment coverage and compliance; and inclusion of parasite
genetic structure regarding sensitivity to ivermectin, will be
essential to evaluate uncertainty surrounding model-derived
projections. This, together with cost-effectiveness analysis, and
development of stochastic frameworks will be crucial for informing
control policy regarding annual vs. biannual treatment strategies
in Africa, and for exploring the feasibility of elimination in foci
with varying degrees of baseline endemicity. Finally, whether
prolonged ivermectin treatment has a profound effect on the
parasite’s reproductive fitness has implications for the risk of
ivermectin resistance evolving [35], and the risk of resurgence
when treatment ceases. This highlights the importance of post-
control surveillance in those foci where treatment is deemed to
have been sufficiently successful to be stopped [62,63,64].
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